CN104055981B - One kind treats bronchiectasic Chinese medicine composition - Google Patents
One kind treats bronchiectasic Chinese medicine composition Download PDFInfo
- Publication number
- CN104055981B CN104055981B CN201410341694.5A CN201410341694A CN104055981B CN 104055981 B CN104055981 B CN 104055981B CN 201410341694 A CN201410341694 A CN 201410341694A CN 104055981 B CN104055981 B CN 104055981B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- bronchiectasis
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of Chinese medicines, and in particular to one kind treats bronchiectasic Chinese medicine composition and preparation method and application.Offer one kind of the invention treats bronchiectasic Chinese medicine composition, it includes 15 parts of following component Chinese ephedra, 6 parts of fructus viticis, 10 parts of honeysuckle, 10 parts of ilex pubescens, 10 parts of Verbena officinalis, 20 parts of dandelion, 20 parts of cicada slough, 10 parts of the tuber of pinellia, 5 parts of the root of bidentate achyranthes, 5 parts of giant knotweed, 10 parts of Radix Glycyrrhizae.The Chinese medicine composition has good therapeutic effect in terms of bronchiectasis is treated, with significant clinical generalization value.
Description
Technical field
The invention belongs to field of medicaments, and in particular to one kind treats bronchiectasic Chinese medicine composition and preparation method thereof
With application.
Background technology
Bronchiectasis is, due to bronchus and its surrounding lung tissue chronic suppurative inflammation and fibrosis, to make bronchial wall
Muscle and elastic fibrous tissue destruction, cause bronchus deform and persistently expansion.It is in chronic process more the bronchiectasis course of disease, can sends out
It is born in any age.Childhood suffers from measles, pertussis or pneumonia medical history after influenza, or has pulmonary tuberculosis, endobraonchial tuberculosis, lung
The medical histories such as fibrosis.Classical symptom is chronic cough, coughs a large amount of phlegms and spit blood repeatedly.Expectoration is from morning, dusk and h.d.
At most, daily up to 100~400ml.Patient's self-induction is light when expectoration is unobstructed；Sputum inadequate drainage, then feel uncomfortable in chest, constitutional symptom
Also substantially aggravate.Being in yellow green purulence sample sputum more, when merging anaerobic infection can stink, collect full-time phlegm and be statically placed in vial
In, 3 layers can be divided into after a few hours：Upper strata is foam, and middle level is yellow green muddiness fester, and lower floor is slough sediment.
90% patient often has spitting of blood, varying degree.Some patients, spitting of blood is probably its starting and only main suit, is clinically referred to as " dry
Property bronchiectasis ", be common in tuberculous bronchiectasis, lesion is more in superior lobar branch tracheae.If scabies secondary infection repeatedly, Bing Renshi
There are heating, night sweat, weak, anorexia, become thin.When the concurrent compensatory of bronchiectasis or obstructive emphysema, patient
Can there are expiratory dyspnea, out of breath or cyanosis, late period may occur in which the performance of pulmonary heart disease and cardiorespiratory failure.
The Antibiotics of Western medicine are clinically used for bronchiectasic treatment at present；As Cefradine, Pefloxacin,
Amoxicillin, SMZco etc., symptom would generally be after medication after medication 1 week eliminated in 6 weeks, but the treatment is answered
Hair rate is higher, long-term taking not only can Chen Sheng antibiont drug resistances, and due to these Western medicine mostly have potential hepatotoxicity,
Action target spot is single, and long-term taking may influence the health status of patient.Therefore a kind of bronchiectasis is researched and developed effectively to control
Medicine is treated to be of great practical significance.
The history of Chinese medicine bronchial disease is of long standing and well established, and as an important side of modern complex treatment
Face, increasingly attracts attention in recent years.This disease is belonged to the categories such as " cough ", " lung carbuncle " by traditional Chinese medicine.Think being invaded by exogenous pathogen,invasion of exogenous pathogen, drink
Eating disloyal, unsuccessful feelings will, overstrain, healthy tendency loss etc. can cause this disease.As catching pathogenic heat, or the heresyization of chill are warm, accumulate
Tie in lung, lung is heated bright, loses that its is clear respectful, and heat stops up blood stasis, pents up into carbuncle；Or phlegm phlogiston is contained, eating and drinking without temperance is addicted to drink, and overfeeding is hot
Savoury, spleen insufficiency makes retention of damp-heat in the interior, and exopathogen is felt again, causes inside and outside conjunction evil and falls ill；Or six feelings it is unsuccessful, stagnation of liver qi, change fire violate
Lung, lung network of burning；Or weakness due to chronic disease, overstrain, undermine lungs, insufficiency of lung-QI,deficiency of lung-QI and fall ill；Or it is fire excess from yin deficiency, burn lung network and
Cause a disease.
China Patent No. is that 2007101310388 patent of invention is disclosed and a kind of treats bronchiectasis hemoptysis
Medicine, is used as medicine, with bletilla, Gardenia, the dried rhizome of rehmannia, distant and out of sight benevolence mud, bulbus fritillariae cirrhosae, raw ephedra, hairyvein agrimony, the root bark of white mulberry, root bark of Chinese wolf-berry etc. for controlling
Treat bronchiectasis hemoptysis.China Patent No. is that 2007101135453 patent of invention discloses one kind and treats bronchiectasis
Chinese medicine composition, be used as medicine with the dried rhizome of rehmannia, Chinese holly leaf, hairyvein agrimony, the tuber of stemona, the bletilla striata, asparagus fern, the wind-weed, the root of straight ladybell, inular flower, for controlling
Treat the branch gas expansion disease of the diseases such as cough spitting of blood.
The research direction of world's new drug is made a general survey of, mainly single chemicals and its system is researched and developed before the eighties
Agent, starts to develop biotechnology and natural medicinal plants after the eighties, and drug research direction tends to diversity.With reference in the modern times
Medical theory of development, from the angle for improving curative effect of medication, reducing side effect, screening extraction is carried out by traditional Chinese medicine ingredients
And/or preparation obtained in compatibility, its Small side effects is safe, with the advantage that chemical synthetic drug can not compare.
The content of the invention
For the deficiency of current bronchiectasis clinical treatment medicine, first purpose of the invention is to provide one kind to control
Bronchiectasic Chinese medicine composition is treated, the Chinese medicine composition has good therapeutic effect in terms of bronchiectasis is treated.
Chinese medicine composition of the present invention, is mainly obtained by the raw material of following weight portion：15 parts of Chinese ephedra, 6 parts of fructus viticis, honeysuckle 10
Part, 10 parts of ilex pubescens, 10 parts of Verbena officinalis, 20 parts of dandelion, 20 parts of cicada slough, 10 parts of the tuber of pinellia, 5 parts of the root of bidentate achyranthes, 5 parts of giant knotweed, Radix Glycyrrhizae 10
Part.Its epheday intermedia, the medicinal part of Verbena officinalis are its stem, and honeysuckle is used as medicine with its pistil, and ilex pubescens, giant knotweed, the root of bidentate achyranthes are with its root
It is used as medicine, Verbena officinalis, dandelion, Radix Glycyrrhizae are used as medicine with its whole herb with root, fructus viticis is used as medicine with its leaf or branches and leaves.
Chinese medicine composition epheday intermedia of the present invention and fructus viticis can play the cooperative effect of dispelling phlegm and eliminating dampness, removing pattogenic heat from the blood and toxic material from the body.Gold
Honeysuckle flower then can be with promoting blood circulation, broken product dredging collateral with Verbena officinalis；Ilex pubescens, cicada slough, giant knotweed and dandelion share can clearing heat and promoting diuresis,
Dispelling wind and heat from the body, dispersing swelling and dissipating binds symptom.Verbena officinalis and Chinese ephedra being capable of heat-clearing and damp-drying drug, dissipating bind inducing diaphoresis.The root of bidentate achyranthes and the tuber of pinellia can blood-nourishing it is soft
Liver, nourishing blood and tranquilization.Radix Glycyrrhizae coordinating the drug actions of a prescription.All medicines share, play altogether dispersing swelling and dissipating binds, activate blood circulation and disperse blood clots, dispelling phlegm and eliminating dampness the effect of.
The method for preparing Chinese medicine composition of the present invention is as follows：Each medicinal material of above-mentioned components by weight percent is taken, dosing material gross weight
5-15 times of water, soaks 10-60 minutes, decocts 1-4 times, each 1-3 hours, and filtration, merging filtrate, filtrate decompression is concentrated into phase
To the medicinal extract of density 1.05-1.25, the relative density is testing result at 60 c, and addition ethanol to alcohol content is
60-90% (v/v), stands 24 hours, takes supernatant, reclaims ethanol to concentrating, and obtains final product.The above-mentioned Chinese medicine composition of the present invention can be with
It is further prepared into the pharmaceutical preparation clinically commonly used, preferably mixture, tablet, capsule.
Invention additionally discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e., above-mentioned Chinese medicine composition is preparing treatment bronchus
Purposes in dilator.Chinese medicine composition of the present invention is used to embody significant anti-infectious function during bronchiectasis, and has
There is the effect of significant antiphlogistic effects and enhancing patient's immunity, have that treats both principal and secondary aspect of disease to control curative effect for bronchiectasis
Really.The embodiment of the present invention 4 is demonstrate,proved by investigating the antiinflammatory action of Chinese medicine composition paraxylene induced mice inflammatory model of the present invention
The Chinese medicine composition that the real present invention is provided can have significant anti-inflammatory efficacy, and its antiphlogistic effects is better than hydrocortisone, wherein
The antiphlogistic effects of high dose group and middle dose group have significant difference (P ＜ 0.05) compared with hydrocortisone, and this shows this
Effect acts synergistically comprehensively, with obvious during the traditional Chinese medicine composition for treating bronchiectasis of invention, achieves unexpected medicine
Thing curative effect.The embodiment of the present invention 5 is by investigating Chinese medicine composition of the present invention in the common pathogen fungistatic effect discovery present invention
Drug composition can play inhibition under very low crude drug concentration to most pathogenic bacteria, and this shows the present invention for thin
There is the low treatment advantage of has a broad antifungal spectrum, antimicrobial concentration during the bronchiectasic treatment of bacterium property.The embodiment of the present invention 6 is by clinic
It is experimentally confirmed that Chinese medicine composition of the present invention can be to bronchiectasic therapeutic effect significantly, total effective rate is up to 90%, significantly
Higher than control group.
In a word, compared with prior art, with treating bronchiectasic activity very well, and the present invention is pure to the present invention
Chinese medicine preparation, is particularly non-toxic to liver to human body.When the present invention is used as bronchodilator treatment medicine, medicine effect
Comprehensively, while soothing liver-qi stagnation, invigorating the spleen treatment for relieving indigestion and constipation, additionally it is possible to which acquirement activates blood circulation and disperses blood clots, effect of dispelling phlegm and eliminating dampness, can rapidly make branch
Tracheaectasy conditions of patients takes a turn for the better；And Chinese medicine composition of the present invention is prepared simply, and substantially nontoxic, raw material is easy to get, and is suitable to masses
Change is used, with good potential applicability in clinical practice.
Specific embodiment
The present invention is further described below by way of specific embodiment, but the present invention is not limited only to following examples.
The scope of the present invention is interior or is not departing from present disclosure, spirit and scope, to Chinese medicine composition of the present invention
It is suitably modified, replaced effect identical component, it will become apparent to those skilled in the art that they is all regarded
To be included within the scope of the present invention.
Part I, the preparation of Chinese medicine composition of the present invention
The Chinese medicine composition mixture of the invention of embodiment 1
Prescription：Chinese ephedra 15g, fructus viticis 6g, honeysuckle 10g, ilex pubescens 10g, Verbena officinalis 10g, dandelion 20g, cicada slough
20g, tuber of pinellia 10g, root of bidentate achyranthes 5g, giant knotweed 5g, Radix Glycyrrhizae 10g.
Preparation method：Take each medicinal material of above-mentioned components by weight percent, 5 times of dosing material gross weight of water soaks 30 minutes, decocts
2 times, 2 hours every time, filtration, merging filtrate, filtrate decompression was concentrated into the medicinal extract of relative density 1.1, and the relative density is 60
Testing result under degree Celsius, it is 75% (v/v) to add ethanol to alcohol content, stands 24 hours, takes supernatant, reclaims ethanol dense
Contracting, adds water to 1000ml, stirs evenly, and dispenses, and flowing steam sterilization 35min obtains final product mixture.
The Chinese medicine composition tablet of the invention of embodiment 2
Prescription：Chinese ephedra 150g, fructus viticis 60g, honeysuckle 100g, ilex pubescens 100g, Verbena officinalis 100g, dandelion 200g,
Cicada slough 200g, tuber of pinellia 100g, root of bidentate achyranthes 50g, giant knotweed 50g, Radix Glycyrrhizae 100g.
Preparation method：Take each medicinal material of above-mentioned components by weight percent, 10 times of dosing material gross weight of water soaks 60 minutes, decocts
Boil 1 time, 1 hour every time, filtration, merging filtrate, filtrate decompression was concentrated into the medicinal extract of relative density 1.25, the relative density be
Testing result under 60 degrees Celsius, it is 80% (v/v) to add ethanol to alcohol content, stands 24 hours, takes supernatant, reclaims ethanol
To concentrating, vacuum drying, granulation, compressing tablet are obtained final product.
The Chinese medicinal composition capsules of the present invention of embodiment 3
Prescription：Chinese ephedra 1500g, fructus viticis 600g, honeysuckle 1000g, ilex pubescens 1000g, Verbena officinalis 1000g, dandelion
2000g, cicada slough 2000g, tuber of pinellia 1000g, root of bidentate achyranthes 500g, giant knotweed 500g, Radix Glycyrrhizae 1000g.
Preparation method：Take each medicinal material of above-mentioned components by weight percent, 8 times of dosing material gross weight of water soaks 45 minutes, decocts
4 times, 1.5 hours every time, filtration, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.2, the relative density be
Testing result under 60 degrees Celsius, it is 90% (v/v) to add ethanol to alcohol content, stands 24 hours, takes supernatant, reclaims ethanol
To concentrating, vacuum drying, granulation is encapsulated to obtain final product.
Part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
The antiinflammatory action of the Chinese medicine composition paraxylene induced mice inflammatory model of the present invention of embodiment 4
Hydrocortisone be it is artificial synthesized be also naturally occurring glucocorticoid, after hydrocortisone enters cell, swash
Cytoplasmic receptor living, enters nucleus after allosteric, combined with DNA response elements, causes the suppression or induction of genetic transcription, makes inflammation
The expression of GAP-associated protein GAP changes.Hydrocortisone has stronger anti-inflammatory activity, is clinically usually used in arthritis, bronchus
The treatment of expansion.
1st, experimental technique：
50 KM mouse, male and female half and half, 25-30 grams of body weight is randomly divided into 5 groups, i.e. model control group, combination group by body weight
High dose group, composition middle dose group, composition low dose group, positive controls, every group 10, each administration group mouse is given respectively
Give following medicines：
Model control group：Gavage gives the physiological saline of same volume；
Positive controls：Gavage gives the hydrocortisone drug solution of 5mg/kg；
Composition high dose group：Gavage gives the Chinese medicine composition of 50mg/kg embodiments 1, and Chinese medicine composition presses crude drug gauge；
Composition middle dose group：Gavage gives the Chinese medicine composition of 20mg/kg embodiments 1, and Chinese medicine composition presses crude drug gauge；
Composition low dose group：Gavage gives the Chinese medicine composition of 5mg/kg embodiments 1, and Chinese medicine composition presses crude drug gauge；
Each administration group is administered once a day, successive administration 7d.The μ l of dimethylbenzene 20 are taken after last dose, each mouse is applied to right
Ear.Each by reagent 0.03ml is taken after 30 minutes and is uniformly applied to mouse right ear respectively, auris dextra is put to death after 3.5 hours to dimethylbenzene, is surveyed
Determine each group mouse or so ear method of double differences.Ear method of double differences assay method：Along two ears are cut at auricle baseline, with 8mm card punch in left and right ear
Auricle is laid at same position, is weighed, the ear method of double differences=auris dextra piece weight-left auricle weight.The ear method of double differences can be used as evaluation anti-inflammatory index.
Experimental result：Determine the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is shown in
Table 1.
Each experimental mice ear method of double differences of table 1 compares
| Group | n | The ear method of double differences (mg) |
| Model control group | 10 | 8.25±1.15 |
| Positive controls | 10 | 6.19±1.24* |
| Composition high dose group | 10 | 2.69±1.75**## |
| Composition middle dose group | 10 | 4.54±1.28**# |
| Composition low dose group | 10 | 5.98±1.36* |
Compare with model control group,*P ＜ 0.05；Compare with model control group,**P ＜ 0.01；
Compare with positive controls,#P ＜ 0.05；Compare with positive controls,##P ＜ 0.01.
Result shows that giving positive drug and Chinese medicine composition of the present invention can obtain significant antiphlogistic effects, wherein this hair
The antiphlogistic effects of bright Chinese medicine composition high dose group and positive controls have a pole significant difference, Chinese medicine composition middle dose group with
Positive controls have significant difference, and this shows high dose group, middle dose group and the low dose group of Chinese medicine composition of the present invention
Antiphlogistic effects to be significantly better than positive controls.
The antibacterial experiment in vitro of the Chinese medicine composition of the present invention of embodiment 5
Strain and culture medium respectively α-hemolytic streptococcus (32209), hemolytic chain that this experiment is used
Coccus (32210), ETEC (44102), proteus vulgaris (49101), Salmonella paratyphi A
(50001), pseudomonas aeruginosa (51252), staphylococcus aureus [26111 (5)], Bacillus influenzae (58529-4), nutrition fine jade
Fat culture medium (in be stranded pharmaceutical biological product calibrating institute)；Opacity tube (Chinese bacterial turbidity standard, Chinese medicine biology combinations calibrating
Institute).
Antibacterial experiment in vitro：1. pastille agar plate is prepared.Tested material is pressed into doubling dilution and prepares different pharmaceutical concentration
Culture medium, heating, pH value needed for modulation each, 121 DEG C of sterilizing 30min are cooled to 45 DEG C.Pour into aseptic flat board (plate d=
65mm, 10ml/ plate), the extension rate of stoste containing tested material (2g/ml) in culture medium is respectively l：2,1：4……
1：1024.Do respective blank culture medium simultaneously.2. it is inoculated with.The young age bacterium for reaching the third generation is taken, 0.9% chlorination is used respectively
Sodium solution is the bacterium solution to be checked of 108cfu/ml by standard opacity tube corrected concentrations, and the respective of different doubling dilutions is inoculated in respectively
Pastille agar surface, while being inoculated with 3 points of parallel point, makes at every containing 2 one bacterium solutions.The liquid-drop diameter of each vaccination is 5-8mm.Treat
After vaccination is dried, upset flat board observes result (while doing blank) in 36 DEG C of constant incubator culture 20h.3. mark is judged
It is accurate.Minimum dilution tested material concentration on the agar plate for occurring without bacterium colony is its minimum inhibitory concentration (MIC).
Chinese medicine composition is as shown in table 2 to the minimal inhibitory concentration of each pathogenic strain in this experiment：
Minimal inhibitory concentration of the Chinese medicine composition of the present invention of table 2 to each pathogenic strain
| Bacterial strain | Minimal inhibitory concentration (MIC, g/ml) | Drug dilution degree |
| α-hemolytic streptococcus | 0.008 | 1：256 |
| Beta hemolytic streptococcus | 0.016 | 1：128 |
| EHEC | 0.032 | 1：64 |
| Proteus vulgaris | 0.016 | 1：128 |
| Salmonella paratyphi A | 0.032 | 1：64 |
| Pseudomonas aeruginosa | 0.064 | 1：32 |
| Bacillus influenzae | 0.016 | 1：128 |
| Staphylococcus aureus | 0.032 | 1：64 |
When bronchiectasis merges acute bacterial infection, common pathogen is haemophilus influenzae, streptococcus pneumonia, detests
Oxygen bacterium etc., the course of disease is long, severe, merge underlying diseases bronchiectasis patient in, the enterobacteriaceae such as white bacterium of kerekou pneumonia is thin
Bacterium and pseudomonas aeruginosa are common.Result shows that Chinese medicine composition of the present invention is respectively provided with suppression well to most pathogenic bacteria
Bacterium effect, with highly important therapeutic potential.
The Chinese medicine composition of the present invention of embodiment 6 is to bronchiectasic clinical observation on the therapeutic effect
1 clinical data
1.1 diagnostic criteria references《Practical clinical practice》、《New Chinese medicine guideline of clinical investigations》And《Consonance endocrine with
Metabolism》In Diagnosis of Bronchiectasis standard draft.
1.2 physical data this clinical intervention research cases totally 160, are all from December, 2011 in December, 2013 in north
The division of respiratory disease outpatient service of capital affiliated hospital of university of TCM and inpatient, age 14-74 Sui.By case be randomly divided into treatment group and
Each 80 of control group.Treatment group man 29, female 51；Average age (47.1 ± 21.6) year；Average course of disease (3.2 ± 4.2) year；
Control group man 31, female 49；Average age (46.4 ± 22.5) year；Average course of disease (3.0 ± 5.1) year；Two groups of physical data
Compare, difference is not statistically significant (P ＞ 0.05), with comparativity.
2 research methods
2.1 treatment methods
Treatment group is given according to the Chinese medicine composition described in the embodiment of the present invention 2, and 500mg/kg, point morning and evening is oral twice.
Control group gives Levofloxacin Hydrochloride Capsules (Shanghai Di Sainuo biological medicines Co., Ltd, lot number：120926202, specification：
100mg/) it is oral, usage and dosage is oral, and be grown up each 0.2g, twice daily.
2.2 criterion of therapeutical effect references《New Chinese medicine guideline of clinical investigations》Draft.
Clinical recovery：Cough and expectoration, spitting of blood stop completely, and respiratory tract other symptoms and sign substantially or entirely disappear, can
Adhere to work.
It is effective：Cough and amount of expectoration are significantly reduced, and spitting of blood stops, and pulmonary rale is significantly reduced or disappeared, and lung x ray examinations are scorching
Property shade significantly absorbs.
Effectively：Cough, expectoration take a turn for the better, and a large amount of spitting of bloods stop, but the still band trace of blood or clot, respiratory symptom, sign in phlegm
Mitigate.
It is invalid：Symptom, sign have no improvement after treatment.
3 experimental results
The Chinese medicine composition of the present invention of table 3 is to bronchiectasic therapeutic effect
| Group | Cure | It is effective | Effectively | It is invalid | Total effective rate |
| Treatment group | 35 | 28 | 10 | 7 | 90% |
| Control group | 10 | 15 | 17 | 38 | 52.5% |
As can be seen from Table 3, Chinese medicine composition of the present invention can be to bronchiectasic therapeutic effect significantly, total effective rate
Up to 90%, it is significantly higher than control group.
Claims (5)
1. one kind treats bronchiectasic Chinese medicine composition, it is characterised in that it is obtained by the bulk drug of following weight portion：Fiber crops
Yellow 15 parts, 6 parts of fructus viticis, 10 parts of honeysuckle, 10 parts of ilex pubescens, 10 parts of Verbena officinalis, 20 parts of dandelion, 20 parts of cicada slough, the tuber of pinellia 10
Part, 5 parts of the root of bidentate achyranthes, 5 parts of giant knotweed, 10 parts of Radix Glycyrrhizae；
Its preparation method is comprised the following steps：Take each medicinal material, 5-15 times of dosing material gross weight of water soaks 10-60 minute, pan-fried
Boil 1-4 times, each 1-3 hours, filtration, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.05-1.25, the phase
It is testing result at 60 c to density, it is 60-90% to add ethanol to alcohol content volume ratio, stands 24 hours, is taken
Clear liquid, reclaims ethanol to concentrating, and obtains final product.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that the Chinese medicine composition is mixture, tablet or capsule
Agent.
3. the Chinese medicine composition described in claim 1 or 2 is preparing the purposes in treating bronchiectasis medicine.
4. the purposes of Chinese medicine composition as claimed in claim 3, it is characterised in that described bronchiectasis is associated with acute
Bacterium infection.
5. the purposes of Chinese medicine composition as claimed in claim 3, it is characterised in that described bacterium is haemophilus influenzae, lung
The white bacterium of scorching streptococcus, kerekou pneumonia or one or more of pseudomonas aeruginosa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410341694.5A CN104055981B (en) | 2014-07-18 | 2014-07-18 | One kind treats bronchiectasic Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410341694.5A CN104055981B (en) | 2014-07-18 | 2014-07-18 | One kind treats bronchiectasic Chinese medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104055981A CN104055981A (en) | 2014-09-24 |
| CN104055981B true CN104055981B (en) | 2017-07-07 |
Family
ID=51544100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410341694.5A Expired - Fee Related CN104055981B (en) | 2014-07-18 | 2014-07-18 | One kind treats bronchiectasic Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104055981B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547667A (en) * | 2014-12-19 | 2015-04-29 | 广东聚智诚科技有限公司 | Traditional Chinese medicine composition for treating chronic bronchitis complicated by emphysema and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011494A (en) * | 2007-01-26 | 2007-08-08 | 广东药学院 | Drop pills for treating asthma cough and preparation method thereof |
| CN103212006A (en) * | 2013-05-20 | 2013-07-24 | 李飞 | Traditional Chinese medicine for treating chronic bronchitis |
| CN103705849A (en) * | 2013-12-27 | 2014-04-09 | 王法红 | Traditional Chinese medicine for treating bronchial asthma |
-
2014
- 2014-07-18 CN CN201410341694.5A patent/CN104055981B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011494A (en) * | 2007-01-26 | 2007-08-08 | 广东药学院 | Drop pills for treating asthma cough and preparation method thereof |
| CN103212006A (en) * | 2013-05-20 | 2013-07-24 | 李飞 | Traditional Chinese medicine for treating chronic bronchitis |
| CN103705849A (en) * | 2013-12-27 | 2014-04-09 | 王法红 | Traditional Chinese medicine for treating bronchial asthma |
Non-Patent Citations (1)
| Title |
|---|
| 支气管扩张的中医病机及辨治规律探讨;林杰豪;《广西中医药》;19900302;第23页右栏第2-4段，第24页左栏1-6段。 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104055981A (en) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167811B (en) | External-applied preparation with anti-inflammation, itching-relieving and sterilization function and manufacturing method and application thereof | |
| CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
| CN100444863C (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN104306837A (en) | Baibei anti-tuberculosis pill for treating pulmonary tuberculosis, tuberculous pleuritis, peritonitis, empyema and bronchopleural fistula | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN104353032B (en) | Medicated wine composition and application thereof | |
| CN103830469A (en) | Chinese medicinal composition for treating purulent meningitis and application thereof | |
| CN104055981B (en) | One kind treats bronchiectasic Chinese medicine composition | |
| CN103816281B (en) | A kind of Chinese medicine composition of prevention and treatment anemopyretic cold | |
| CN1330349C (en) | Chinese medicine composition for treating urethra infection and preparing method | |
| CN103142733B (en) | Chinese medicine composition for treating upper respiratory infection | |
| CN101780211B (en) | Traditional Chinese medicine for treating infantile chronic cough and asthma | |
| CN104666594A (en) | Moxibustion stick for treating tinea pedis and preparation method thereof | |
| CN103211067A (en) | Food-grade health tea granules capable of clearing heat from throat | |
| CN103977254A (en) | Traditional Chinese medicine preparation for treating infant suppurative tonsillitis and nursing method thereof | |
| CN113813306B (en) | Traditional Chinese medicine composition for preventing and treating infectious rhinitis of chicken | |
| CN102671036A (en) | Chinese medicine oral liquid for treating chronic lung abscess and preparing method thereof | |
| CN101810675A (en) | Medicament for treating pharyngitis | |
| CN108498649B (en) | Scorpion-astragalus root ointment | |
| CN104887973A (en) | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough | |
| CN106266557A (en) | A kind of Chinese medicine preparation treating colpitis mycotica | |
| CN105168838A (en) | Traditional Chinese medicine composition for treating sphagitis and preparation thereof | |
| CN105147909A (en) | Chinese herb decoction for treating meningitis and preparation method thereof | |
| CN104958530A (en) | Traditional Chinese medicinal composition for treating infantile pneumonia | |
| CN104971210A (en) | External lotion for treating tinea pedis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Han Ping Inventor after: Zhang Na Inventor after: Guo Ruiyou Inventor before: Chen Yuanzheng |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170612 Address after: Shibei District People's road 266000 Shandong city of Qingdao province No. 4 Applicant after: Han Ping Address before: 276017 Shandong, Linyi, Luozhuang District Commercial Street, No. 31 Applicant before: Chen Yuanzheng |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170707 Termination date: 20190718 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |